We're actually in a great place to reverse aging already with off the shelf stuff you can get from the grey market. We have countless interventions that show improvements in aging-related metrics in humans that show verified longevity benefits in animal models. That's about as good as you can hope for without waiting a lifetime to actually confirm the human actuarial benefit, which is inherently a losing strategy.